What is CJC-1295 + Ipamorelin?
Understanding two research peptides investigated for their distinct effects on growth-hormone signalling.
CJC-1295 and Ipamorelin are research peptides that interact with the growth-hormone axis through different biological pathways. CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, while Ipamorelin is a selective growth hormone secretagogue that acts at the ghrelin receptor. Researchers study these compounds individually and together to better understand pituitary signalling, growth-hormone secretion and IGF-1 regulation.
Quick Answer
CJC-1295 + Ipamorelin combines a growth hormone-releasing hormone analogue with a ghrelin-receptor agonist. Both stimulate growth-hormone release, but they act through separate receptor pathways, making the combination relevant to research into pituitary signalling, hormone pulsatility and the GH/IGF-1 axis.
Direct clinical evidence specifically investigating the combination remains limited, so findings from either peptide alone should not automatically be attributed to the blend.
Table of Contents
- What is CJC-1295 + Ipamorelin?
- What is CJC-1295?
- What is Ipamorelin?
- How does the combination work?
- What is the GH/IGF-1 axis?
- Why is CJC-1295 + Ipamorelin being researched?
- Current areas of scientific research
- Frequently Asked Questions
- References
What is CJC-1295 + Ipamorelin?
CJC-1295 + Ipamorelin is a research combination involving two synthetic peptides that influence growth-hormone secretion through separate signalling mechanisms.
CJC-1295 acts as an analogue of naturally occurring growth hormone-releasing hormone, commonly abbreviated to GHRH.
Ipamorelin belongs to a class of compounds known as growth hormone secretagogues. It activates the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a.
Both pathways communicate with the pituitary gland, but they do so through different receptors. This complementary activity is the main scientific rationale for researching the peptides together.
What is CJC-1295?
CJC-1295 is a synthetic GHRH analogue developed to stimulate endogenous growth-hormone secretion.
Naturally occurring GHRH has a relatively short duration of action. CJC-1295 was engineered to resist rapid degradation and, in its drug-affinity-complex form, bind to circulating albumin. This substantially extends its biological activity.
Human studies of long-acting CJC-1295 found prolonged increases in circulating growth hormone and IGF-1 following administration.
CJC-1295 with DAC and without DAC
The name CJC-1295 is used inconsistently in the research-peptide market.
The original CJC-1295 contains a drug affinity complex, or DAC, which allows it to bind to albumin and remain active for an extended period.
Products described as CJC-1295 without DAC are usually shorter-acting modified GRF 1-29 peptides. Although closely related, they should not be treated as pharmacologically identical to the original long-acting CJC-1295.
What is Ipamorelin?
Ipamorelin is a synthetic peptide and selective growth hormone secretagogue.
It activates the ghrelin receptor, which is involved in growth-hormone release and several other physiological processes. Early research identified Ipamorelin as comparatively selective for growth-hormone release, with less activation of ACTH and cortisol than some earlier secretagogues in the experimental models studied.
Research has also examined Ipamorelin in relation to gastrointestinal motility because ghrelin-receptor signalling affects movement through the digestive tract. This includes animal studies and a phase-two clinical study involving postoperative ileus.
How Does the Combination Work?
The two peptides target different receptors associated with pituitary growth-hormone release.
CJC-1295 pathway
CJC-1295 binds to GHRH receptors on cells in the anterior pituitary gland.
This reproduces part of the signalling produced by naturally occurring GHRH and encourages the pituitary to release growth hormone.
Ipamorelin pathway
Ipamorelin activates the growth hormone secretagogue receptor.
This receptor is also activated by ghrelin, a naturally occurring hormone involved in growth-hormone regulation, appetite and gastrointestinal activity. The discovery of ghrelin helped establish that this receptor pathway is distinct from the traditional GHRH pathway.
Combined research rationale
Because CJC-1295 and Ipamorelin act through separate receptors, researchers are interested in whether activating both pathways may produce a different growth-hormone response than activating either one alone.
However, robust human trials specifically assessing the combined formulation are lacking. The biological rationale should therefore be distinguished from established clinical evidence.
What is the GH/IGF-1 Axis?
The growth hormone and insulin-like growth factor-1 axis is an endocrine signalling system involving the hypothalamus, pituitary gland, liver and other tissues.
The simplified pathway is:
Hypothalamic and peripheral signals → pituitary growth-hormone release → increased IGF-1 production and downstream signalling
Growth hormone can act directly on tissues, while also stimulating the production of IGF-1, particularly in the liver.
This system contributes to research involving:
- Growth and development
- Protein and lipid metabolism
- Glucose regulation
- Tissue maintenance
- Body composition
- Endocrine communication
- Hormonal pulsatility
CJC-1295 research has demonstrated activation of this axis through increases in growth hormone and IGF-1.
Why is CJC-1295 + Ipamorelin Being Researched?
The combination attracts scientific interest because it brings together two different methods of stimulating endogenous growth-hormone release.
Researchers may use these compounds to explore:
- GHRH-receptor signalling
- Ghrelin-receptor signalling
- Pituitary function
- Growth-hormone pulsatility
- IGF-1 regulation
- Interactions between two secretagogue pathways
- Endocrine and metabolic physiology
CJC-1295 has also been studied independently in relation to visceral adiposity and HIV-associated visceral obesity, although this does not establish an equivalent effect for Ipamorelin or for the combined product.
Current Areas of Scientific Research
Current or historical research involving the individual compounds includes:
- Growth-hormone secretion
- IGF-1 signalling
- Pituitary receptor activation
- Hormonal pulsatility
- Ghrelin-receptor biology
- Gastrointestinal motility
- Visceral adipose tissue
- Metabolic physiology
- Analytical detection and peptide metabolism
The evidence base is stronger for the mechanisms of each individual peptide than it is for the commercially encountered CJC-1295 and Ipamorelin combination.
Neither compound should be assumed to reproduce the established clinical uses of approved growth-hormone therapies.
Frequently Asked Questions
Are CJC-1295 and Ipamorelin the same peptide?
No. CJC-1295 is a GHRH analogue, while Ipamorelin is a growth hormone secretagogue and ghrelin-receptor agonist.
Why are CJC-1295 and Ipamorelin combined?
They act through different receptors involved in growth-hormone secretion. The combination is researched to investigate how simultaneous activation of these pathways affects pituitary signalling and the GH/IGF-1 axis.
Is CJC-1295 a growth hormone?
No. It is a synthetic GHRH analogue that signals the pituitary gland to release endogenous growth hormone.
Is Ipamorelin a form of ghrelin?
No. Ipamorelin is synthetic, but it activates the same growth hormone secretagogue receptor associated with ghrelin signalling.
What does DAC mean in CJC-1295?
DAC stands for drug affinity complex. It enables CJC-1295 to bind to albumin, extending its duration of activity.
Is CJC-1295 without DAC identical to CJC-1295 with DAC?
No. The terms are frequently used interchangeably by suppliers, but the original DAC-containing CJC-1295 has different pharmacokinetic characteristics from shorter-acting modified GRF 1-29 formulations.
Does Ipamorelin increase cortisol?
An early experimental study reported that Ipamorelin displayed greater selectivity for growth-hormone release than some older secretagogues and did not produce comparable ACTH or cortisol responses in the models tested. That should not be interpreted as proof that it can never affect these hormones in humans.
Has the CJC-1295 and Ipamorelin combination been extensively studied in humans?
No. Human research exists for CJC-1295 and Ipamorelin individually, but strong clinical evidence specifically evaluating the combined formulation is limited.
Is CJC-1295 + Ipamorelin approved as a medicine?
The research combination is not an approved general treatment for increasing growth hormone, changing body composition or improving physical performance.
References
- Prolonged Stimulation of Growth Hormone and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of Growth Hormone-Releasing Hormone, in Healthy Adults — Teichman SL, et al.
- Once-Daily Administration of CJC-1295, a Long-Acting Growth Hormone-Releasing Hormone Analogue, Normalizes Growth in Growth Hormone-Deficient Mice — Alba M, et al.
- Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analogue — Jetté L, et al.
- Pulsatile Secretion of Growth Hormone Persists During Continuous Stimulation by CJC-1295, a Long-Acting GHRH Analogue — Ionescu M, et al.
- Ipamorelin, the First Selective Growth Hormone Secretagogue — Raun K, et al.
- Efficacy of Ipamorelin, a Novel Ghrelin Mimetic, in a Rodent Model of Postoperative Ileus — Venkova K, et al.
- Prospective, Randomized, Controlled, Proof-of-Concept Study of the Ghrelin Mimetic Ipamorelin for the Management of Postoperative Ileus in Bowel Resection Patients — Beck DE, et al.
- Ghrelin Is a Growth-Hormone-Releasing Acylated Peptide from Stomach — Kojima M, et al.